JP2020517646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517646A5 JP2020517646A5 JP2019556922A JP2019556922A JP2020517646A5 JP 2020517646 A5 JP2020517646 A5 JP 2020517646A5 JP 2019556922 A JP2019556922 A JP 2019556922A JP 2019556922 A JP2019556922 A JP 2019556922A JP 2020517646 A5 JP2020517646 A5 JP 2020517646A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide
- cancer
- population
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 70
- 108091034117 Oligonucleotide Proteins 0.000 claims description 59
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 150000004713 phosphodiesters Chemical group 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims description 4
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 108091012583 BCL2 Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000011319 anticancer therapy Methods 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023013890A JP2023052819A (ja) | 2017-04-19 | 2023-02-01 | Ｂｃｌ２阻害のためのｐ－エトキシ核酸 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487302P | 2017-04-19 | 2017-04-19 | |
| US62/487,302 | 2017-04-19 | ||
| PCT/US2018/028267 WO2018195253A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for bcl2 inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023013890A Division JP2023052819A (ja) | 2017-04-19 | 2023-02-01 | Ｂｃｌ２阻害のためのｐ－エトキシ核酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517646A JP2020517646A (ja) | 2020-06-18 |
| JP2020517646A5 true JP2020517646A5 (https=) | 2021-05-20 |
| JP7284709B2 JP7284709B2 (ja) | 2023-05-31 |
Family
ID=63856080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556922A Active JP7284709B2 (ja) | 2017-04-19 | 2018-04-19 | Ｂｃｌ２阻害のためのｐ－エトキシ核酸 |
| JP2023013890A Withdrawn JP2023052819A (ja) | 2017-04-19 | 2023-02-01 | Ｂｃｌ２阻害のためのｐ－エトキシ核酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023013890A Withdrawn JP2023052819A (ja) | 2017-04-19 | 2023-02-01 | Ｂｃｌ２阻害のためのｐ－エトキシ核酸 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12234457B2 (https=) |
| EP (1) | EP3612160A4 (https=) |
| JP (2) | JP7284709B2 (https=) |
| KR (1) | KR102775924B1 (https=) |
| CN (1) | CN110636835A (https=) |
| AU (1) | AU2018254468B2 (https=) |
| BR (1) | BR112019021775A2 (https=) |
| EA (1) | EA201992490A1 (https=) |
| IL (1) | IL269616A (https=) |
| SG (1) | SG11201909649SA (https=) |
| WO (1) | WO2018195253A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362563A1 (en) | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| JP7132911B2 (ja) | 2016-09-16 | 2022-09-07 | バイオ－パス ホールディングス， インコーポレイテッド | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5248671A (en) | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US6111094A (en) | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| ATE164515T1 (de) | 1993-11-05 | 1998-04-15 | Amgen Inc | Herstellung von liposomen und verfahren zur substanzverkapselung |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7309692B1 (en) | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7262173B2 (en) | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| WO2000040592A1 (en) | 1998-12-30 | 2000-07-13 | Oligos Etc. Inc. | Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| WO2001026625A2 (en) | 1999-10-08 | 2001-04-19 | Alza Corp | Neutral-cationic lipid for nucleic acid and drug delivery |
| US20050186264A1 (en) | 2000-10-12 | 2005-08-25 | Kiani Mohammad F. | Targeting drug/gene carriers to irradiated tissue |
| US7060690B2 (en) * | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
| US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| US20030147813A1 (en) | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US8969314B2 (en) | 2003-07-31 | 2015-03-03 | Regulus Therapeutics, Inc. | Methods for use in modulating miR-122a |
| EP1670955A2 (en) | 2003-09-22 | 2006-06-21 | Rosetta Inpharmatics LLC. | Synthetic lethal screen using rna interference |
| ES2636470T3 (es) | 2004-04-09 | 2017-10-05 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20080171718A1 (en) | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
| CA2704853C (en) | 2007-11-06 | 2017-08-15 | Eugen Uhlmann | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
| CN102239178B (zh) | 2008-10-02 | 2017-06-23 | Vib研究所 | 抑制PlGF以治疗费城染色体阳性白血病 |
| WO2012024396A2 (en) * | 2010-08-17 | 2012-02-23 | Rutgers, The State University Of New Jersey | Compositions and methods for delivering nucleic acid molecules and treating cancer |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| US9322015B2 (en) | 2011-03-09 | 2016-04-26 | The Brigham And Women's Hospital, Inc. | Methods of using microRNA-26a to promote angiogenesis |
| CN103562215B (zh) | 2011-04-01 | 2017-04-26 | 埃西斯药品公司 | 信号转导及转录激活蛋白3(stat3)表达的调节 |
| EP3003275B1 (en) | 2013-06-03 | 2020-11-18 | Bar-Ilan University | Liposomes for modulating wiskott-aldrich syndrome protein |
| US10182988B2 (en) | 2013-12-03 | 2019-01-22 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| CA2982205A1 (en) | 2015-04-10 | 2016-10-13 | David W. Andrews | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| EP3362563A1 (en) | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| JP7132911B2 (ja) | 2016-09-16 | 2022-09-07 | バイオ－パス ホールディングス， インコーポレイテッド | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
| EP3592841B1 (en) | 2017-03-09 | 2024-02-14 | Thomas Jefferson University | Compositions for treating cancers using antisense |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| WO2018195250A1 (en) | 2017-04-19 | 2018-10-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for igf-1r inhibition |
| JP2020517645A (ja) | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス， インコーポレイテッド | Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸 |
| WO2020198587A1 (en) | 2019-03-28 | 2020-10-01 | Thomas Jefferson University | Methods for treating cancers using antisense |
| CN112830354A (zh) | 2019-11-22 | 2021-05-25 | 富泰华工业（深圳）有限公司 | 基于区块链系统的电梯调度系统、装置、方法及存储介质 |
-
2018
- 2018-04-19 EP EP18787952.3A patent/EP3612160A4/en active Pending
- 2018-04-19 KR KR1020197033985A patent/KR102775924B1/ko active Active
- 2018-04-19 CN CN201880033234.2A patent/CN110636835A/zh active Pending
- 2018-04-19 JP JP2019556922A patent/JP7284709B2/ja active Active
- 2018-04-19 BR BR112019021775A patent/BR112019021775A2/pt unknown
- 2018-04-19 AU AU2018254468A patent/AU2018254468B2/en active Active
- 2018-04-19 WO PCT/US2018/028267 patent/WO2018195253A1/en not_active Ceased
- 2018-04-19 US US16/606,443 patent/US12234457B2/en active Active
- 2018-04-19 EA EA201992490A patent/EA201992490A1/ru unknown
- 2018-04-19 SG SG11201909649S patent/SG11201909649SA/en unknown
-
2019
- 2019-09-24 IL IL26961619A patent/IL269616A/en unknown
-
2023
- 2023-02-01 JP JP2023013890A patent/JP2023052819A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517632A5 (https=) | ||
| JP2020517646A5 (https=) | ||
| US10149905B2 (en) | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | |
| JP2018534361A5 (https=) | ||
| JP2022050550A5 (https=) | ||
| CN108026533B (zh) | 拮抗性pdl1适体及其在癌症治疗中的应用 | |
| IL269608B1 (en) | Compounds Containing Phosphorus-Ethoxy-Based Nucleic Acids for STAT3 Inhibition for Use in the Treatment of Cancer and Autoimmune Diseases | |
| CN110643609B (zh) | 一种核苷类似物药物分子构建的药物适配体及其制备方法和应用 | |
| US8552167B2 (en) | Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing | |
| JP2020517645A5 (https=) | ||
| JP2020517631A5 (https=) | ||
| Hu et al. | Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-MiR-21 and 5-fluorouridine | |
| CN110072530A (zh) | 4′-磷酸酯类似物和包含其的寡核苷酸 | |
| JP2008540363A5 (https=) | ||
| JP2011172597A (ja) | スプライス領域アンチセンス組成物および方法 | |
| JP2018519831A5 (https=) | ||
| WO2017200787A1 (en) | Peptide-dna chimeras for treatment of her overexpressing cancers | |
| US20210171957A1 (en) | Methods and agents for enhancing t cell therapies | |
| US11008575B2 (en) | DNA aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer | |
| US20210267897A1 (en) | Therapeutic Nanoparticles and Related Compositions, Methods and Systems | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| CN103834035A (zh) | 一种阳离子化昆布多糖及其制备方法和应用 | |
| Normanno et al. | Amphiregulin anti‐sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line | |
| WO1999020283A1 (fr) | Activateur de nuclease de cellules intracancereuses | |
| TWI589307B (zh) | Novel manufacturing method for local administration of lipid complex and antitumor agent using the lipid complex |